Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
about
Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.Prefrontal cortex white matter tracts in prodromal Huntington diseaseSex Differences in Circadian Dysfunction in the BACHD Mouse Model of Huntington's DiseaseDisruption of response inhibition circuits in prodromal Huntington disease.The involvement of secondary neuronal damage in the development of neuropsychiatric disorders following brain insults.Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD StudyStudies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory DysfunctionPrediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational studyLongitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study.Onset of Huntington's disease: can it be purely cognitive?Everyday cognition in prodromal Huntington diseaseCognitive and autonomic dysfunction in presymptomatic and early Huntington's disease.Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicityProgressive cognitive deficit, motor impairment and striatal pathology in a transgenic Huntington disease monkey model from infancy to adulthood.Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic BurdenLongitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's DiseaseInteraction without intent: the shape of the social world in Huntington's diseaseNetwork topology and functional connectivity disturbances precede the onset of Huntington's disease.Prospects for neuroprotective therapies in prodromal Huntington's disease.The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation.Potential therapeutic targets in polyglutamine-mediated diseases.Validation of a prognostic index for Huntington's disease.Huntington's Disease-Update on Treatments.Informativeness of Early Huntington Disease Signs about Gene Status.Preliminary analysis using multi-atlas labeling algorithms for tracing longitudinal change.Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.The impact of oculomotor functioning on neuropsychological performance in Huntington disease.The Neuropsychology of Huntington's Disease.Egocentric and allocentric visuospatial working memory in premotor Huntington's disease: A double dissociation with caudate and hippocampal volumes.Huntington's Disease: Premotor Phase.Progress in developing transgenic monkey model for Huntington's disease.Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.Preclinical progression of neurodegenerative diseases
P2860
Q27333729-C358F918-0035-4A59-8075-6B559B735827Q27335055-A226A6EB-0981-439F-892E-3F52FF3FBE01Q28386809-493CB782-6253-4622-90F8-BDB1B83A2255Q30403689-1E8927E4-C289-4BA3-B45A-BBBCBC55A991Q30441452-5567D52F-884F-45EB-9881-9566CB88C118Q30577157-0F4B5D9A-7E3F-4EE5-BDE2-0718D9E8E40EQ30581974-170BEB15-A4D8-4D40-8E01-FE8CAC552232Q30631995-271456D0-5826-4902-8B3D-F0D3D40FBCC5Q30855262-502AEA2B-E351-4319-822A-0CD344634602Q31162777-9B30F168-8486-4F76-9411-E1373F8E0833Q34322005-23716EBB-3E99-44F1-8236-1FFE669FD35DQ34861585-D7C0FF51-ED79-4C05-BCD0-712AD6D1660AQ35137786-481D75E0-11DC-4251-BCD2-96C5DDFC9290Q35561965-723E0259-54D8-4165-82FB-403998FDF17DQ35597258-DEA80741-FF21-48C5-8028-798DCC830767Q35997096-0A234648-A394-4459-8A23-A4109EAC01CDQ36021158-F96B3586-B852-4571-8C30-D9473407E3A3Q36030634-CD35C018-163C-4184-8E75-6265E5F02D50Q37255302-B39AD8D7-0268-483A-949C-2010601195ADQ38191477-3465099A-54C3-4B18-8813-76A0C6F148BCQ38206500-7E3154F7-A73C-4C82-8EC8-68FC209F65C5Q38246221-73DDB46D-2EE0-4260-A626-A81395F9C4A6Q38790095-28605904-08CC-4CFC-BC53-84460A70F955Q39190617-2717A05C-734B-4A2D-9939-D574BBF30B02Q40458680-1F74A753-87EB-4907-B9EB-8BF5D9298016Q40667242-4EAD20C0-64D3-454D-B7FD-56FE1FE3EE28Q41842696-BD3FC6DD-9423-412C-85BC-D8D8BA82405DQ42194515-25764949-608F-482C-BCC8-4D0113D26B27Q45292458-4CEA7365-EE71-4651-B0D8-77C6C21B0967Q45304583-9DD42B9B-3560-4CE4-8E81-B90E9FF38B72Q46051258-B6058C93-56B6-4AF7-BA52-F1F6F6BDAB27Q47288617-073BDE4D-EA5C-4FD3-84C5-A724BF9B6440Q47974512-30DBBB2B-D762-4C46-B73E-AF192FC761D6Q49659203-055590CB-83DD-430F-96E2-CB441443D0E8Q58804706-B64BFCDF-E6A2-487E-9531-C7F46C770646
P2860
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@en
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@nl
type
label
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@en
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@nl
prefLabel
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@en
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@nl
P2860
P356
P1476
Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
@en
P2093
Megan M Smith
PREDICT HD investigators and Coordinators of the Huntington Study Group
P2860
P304
P356
10.1136/JNNP-2013-305114
P407
P577
2013-08-02T00:00:00Z